MENLO PARK, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, announced that it is presenting preliminary data from the Phase 1/2 study of its proprietary, selective cortisol modulator, relacorilant, in combination with nab-paclitaxel (Celgene Corporation’s drug, Abraxane®) to treat patients with solid tumors. The data will be exhibited today in a poster at the 2018 American Society of Clinical Oncology (ASCO) Meeting in Chicago, Illinois (June 1 – 5).
“Data from the initial, dose-finding portion of this trial are striking,” said Robert S. Fishman, MD, Corcept’s Chief Medical Officer. “These patients have advanced disease. Before enrolling in this study, they had already undergone, on average, 3.7 lines of therapy. Nonetheless, of the patients who received at least 100 mg of relacorilant and 80 mg/m2 of nab-paclitaxel, four of nine with pancreatic cancer exhibited durable disease control, as did four of seven with ovarian cancer. In some cases, the period of control was exceptionally lengthy – lasting more than 50 weeks in a patient with pancreatic cancer; and 42 weeks (so far) in a patient with ovarian cancer. All of these patients had received one or more courses of taxane-based monotherapy previously and had their disease progress. We look forward to exploring this regimen’s safety and efficacy in more definitive studies.”
|Monday, June 4, 2018|
|Poster No. 2554|
A Phase 1/2 study of relacorilant + nab-paclitaxel (nab-pac) in patients (pts) with solid tumors:
The dose-finding phase.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Corcept has a large portfolio of proprietary compounds, including relacorilant, that modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the use of cortisol modulators in the treatment of a wide variety of serious disorders, including Cushing’s syndrome. It also holds composition of matter patents covering its selective cortisol modulators.
Abraxane® is a trademark of Celgene Corporation.